| Fri, 09 Apr 2021 18:00:42: | AACR: In redemption of the PI3K drug class, Bayer's Aliqopa leaps ahead of Gilead's Zydelig in lymphoma
|
| Fri, 09 Apr 2021 15:37:05: | J&J chief Gorsky's $29.6M pay package prompts pushback from top proxy advisers ISS and Glass Lewis: report
|
| Fri, 09 Apr 2021 15:13:22: | Vertex CEO Kewalramani collects $9.1M in 2020 pay, less than her biopharma peers
|
| Fri, 09 Apr 2021 14:09:06: | Amgen teams up for digital rehab app in Europe to prevent repeat heart attacks
|
| Fri, 09 Apr 2021 13:45:02: | Emergent's Baltimore plant flagged for quality control concerns last April, FDA report reveals
|
| Fri, 09 Apr 2021 13:21:27: | Johnson & Johnson's COVID-19 vaccine under scrutiny at EMA after 4 'serious cases' of unusual blood clots
|
| Fri, 09 Apr 2021 08:54:00: | Fierce Pharma Asia—Takeda-CSL COVID fail; Daiichi Sankyo's new 5-year plan; Legend-J&J CAR-T filing
|
| Thu, 08 Apr 2021 22:41:17: | FierceMadness winner GSK ViiV's Dovato collage campaign draws complete picture of people living with HIV
|
| Thu, 08 Apr 2021 14:37:49: | Did pharma overshoot digital sales rep calls? Study charts decline in effectiveness
|
| Thu, 08 Apr 2021 14:26:23: | GSK's ViiV Healthcare continues cabaret campaign to engage and inspire HIV community
|
| Thu, 08 Apr 2021 14:10:20: | 'Very stressed' Serum Institute asks government for $400M vaccine production boost
|
| Thu, 08 Apr 2021 13:50:05: | BeiGene's massive biologics plant in China wins first commercial manufacturing nod
|
| Thu, 08 Apr 2021 13:37:42: | Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
|
| Wed, 07 Apr 2021 18:31:05: | AstraZeneca COVID-19 shot tagged with new warning in EU, highlighting rare blood clot risk
|
| Wed, 07 Apr 2021 15:11:55: | Cannes Lions Health goes virtual, giving up on a live show this year
|
| Wed, 07 Apr 2021 14:29:59: | J&J scores backing from Chamber of Commerce, PhRMA and more in Supreme Court appeal of $2.1B talc verdict
|
| Wed, 07 Apr 2021 14:03:10: | More relief for Dupixent as FDA pushes back Lilly, Pfizer eczema decisions on safety concerns
|
| Wed, 07 Apr 2021 14:01:25: | Ionis lays off majority of Akcea staff, expands Sobi Tegsedi deal
|
| Wed, 07 Apr 2021 13:45:52: | Bristol's new myeloma CAR-T needs a hefty discount to be cost-effective, watchdogs say while endorsing GSK's Blenrep
|
| Tue, 06 Apr 2021 15:47:41: | Amarin launches Vascepa in all-important Europe as it slowly bleeds share to U.S. generic
|
| Tue, 06 Apr 2021 15:19:42: | With sales on the upswing, Amgen CEO Bradway scores a $20M pay package for 2020
|
| Tue, 06 Apr 2021 15:01:32: | Teva joins pharma's help-the-helpers trend with campaign for Canada's COVID caregivers
|
| Tue, 06 Apr 2021 15:00:58: | AstraZeneca's Amaze platform aims to simplify chronic disease management—and put patients and docs on same page
|
| Tue, 06 Apr 2021 14:53:31: | CDMO Sterling, scaling up for the oncology arms race, acquires U.K. antibody-drug conjugate specialist
|
| Tue, 06 Apr 2021 13:48:56: | Supernus gears up for Q2 Qelbree launch, in time for back-to-school ADHD script season
|
